ClinicalTrials.gg
RecruitingNCT07945171Updated Nov 18, 2026

Role of Perioperative Dexmedetomidine on Intraoperative Hemodynamics and Neuro-endocrine Response in Patients Undergoing Robot-Assisted Gynecological Surgery

A Phase 4 interventional study of Dexmedetomidine and Normal Saline in Perioperative Role of Dexmedetomidine on Cortisol Level in Robotic Hysterectomy, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to female participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2026, registered Sep 2026).
  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
Female
01

Study summary

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

Read the detailed description

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

  1. Pre-operative settings:

    Preoperative evaluation of full medical history, laboratory investigations in form of complete blood count, blood sugar, liver function tests, kidney function tests, serum electrolytes and coagulation profile and for fulfilling inclusion criteria. Patients will be trained how to use visual analogue scale (VAS).

    Patients will be divided into two groups:

    Group D :(n = 25) will receive (1 μg/kg) of dexmedetomidine as a loading intravenously for 10 min before anesthesia induction and will be continuously infused at 0.2 μg/kg/h intraoperatively.

    Group P: (n = 25) will receive The same volume of normal saline in the same manner to group D.

  2. Intraoperative Settings:

All patients will receive the standard technique of general anesthesia by the supervisors of the research. Two intravenous wide pore accesses will be secured, one for routine fluids and the other exclusively for Dex. All the patients will receive pantoprazole 40 mg and Ondansetron 4mg intravenously 15 min before induction and Loading dose of Dex infusion 1 mcg/kg will be started and continued for 10 minutes for group D and Normal saline with the same volume will be given to group P in the same manner.

ECG, non-invasive blood pressure and pulse oximeter will be established upon the patient's arrival in the operating room. Induction of anesthesia in both groups will be done by intravenous 1-2 mg/kg propofol, 1mic/kg fentanyl and 0.5 mg/kg atracurium.

Maintenance will be achieved with appropriate sized cuffed endotracheal tube passed orally, and the placement will be confirmed with auscultation and end-tidal carbon dioxide (EtCO2) reading. Anesthesia will be maintained with air and oxygen mixture (60:40), and isoflurane, using a closed circuit , top-up doses of atracurium , and the rate of Dex infusion will be changed to a maintenance infusion of 0.2 mcg/kg/h for group D and the same with normal saline for group P. End-tidal concentration of isoflurane will be monitored by measuring the average concentration and its total dosage through the infrared multi-gas analyzers. Vasopressor response to laryngoscopy and intubation will be documented by noting HR and BP. The lungs will be ventilated by maintaining a tidal volume of 6-8 ml/kg, and a respiratory rate to keep ETCO2 at 35-40 mmHg with continuous monitoring.

Intra-operative bradycardia (pulse rate \<50) will be treated with atropine 0.6 mg.

Intra-operative hypotension will be treated with intravenous crystalloids and by reducing the isoflurane concentration and ephedrine. An increase in HR and/or mean arterial pressure (MAP) >20% from baseline values will be treated by 1 mcg/kg of intravenous fentanyl. If there will be no response within 5 min, the initial isoflurane concentration will be increased by 0.2% increment every 4 min up to a maximum of 1% end-tidal concentration. Any additional requirement of lapetalol or nitroglycerine to control BP will be noted Isoflurane inhalation will be stopped 10 min before the end of surgery and dexmedetomidine will be stopped at the end of skin incision closure. The total amount of fentanyl administered during each case will be also recorded.

Blood samples will be analyzed for blood Serum cortisol level, serum glucose and serum lactate.

Serum cortisol level preoperatively (baseline), just after incision, at 6 h after anesthesia induction, at 12 h after induction and at 24 h after induction.

Serum glucose level preoperatively (baseline), just after incision and at 6 h after anesthesia induction.

Serum lactate level preoperatively (baseline), just after incision, at 6 h after anesthesia induction and at 12 h after induction.

  1. Hemodynamic monitoring:

    Intraoperative monitoring was documented during the pre-induction, after the loading dose of Dex, at the induction of anesthesia, during laryngoscopy and intubation, and at pneumoperitoneum and then every 30 min till the end of surgery and continued during extubation and post operatively for 1 hr every 30 min.

  2. Assessment of post-operative pain \& sedation:

By the end of surgery, anesthesia will be discontinued and reversal will be given (when full muscle power regained) as neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Extubation will be done, and the patient will be transferred to the PACU.

02

Conditions studied

  • Perioperative Role of Dexmedetomidine on Cortisol Level in Robotic Hysterectomy
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged from 21-60 years.
  • Patients undergoing elective Robot-Assisted gynecological surgery under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • and ASA IV.
  • A known history of allergy to the drugs used.
  • Patients on chronic therapy.
  • Patient with cardiovascular disorder (Bradycardia, heart block, heart failure).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Group D (Dexmedetomidine)

    Receives IV dexmedetomidine loading dose (1 μg/kg over 10 minutes before anesthesia induction) followed by a continuous infusion (0.2 μg/kg/h) until 15 minutes before the end of surgery.

    Drug: Dexmedetomidine

  • Placebo comparator
    Group P (Placebo)

    Receives normal saline in the same volume and infusion rate schedule as Group D (loading dose over 10 minutes before induction, followed by continuous infusion).

    Drug: Normal Saline

Interventions

  • IV loading dose of 1 μg/kg over 10 min prior to induction, then maintenance infusion of 0.2 μg/kg/h until 15 min prior to surgery end.

  • DrugNormal Saline

    Equivalent volume of normal saline solution administered as an IV loading dose and continuous infusion matching the study drug timeline.

06

What researchers measure

Primary outcomes

  1. Serum Cortisol Level

    Evaluation of the perioperative neuro-endocrine stress response by measuring blood serum cortisol levels.

    Time frame: Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Secondary outcomes

  1. Time to First Rescue Analgesia

    The time interval between the completion of drug injection and the participant's first post-operative request for pain relief administered when Numerical Pain Distress Scale above 4 as • 0: No pain * 1-3: Mild pain * 4-6: Moderate pain * 7-10: Severe pain

    Time frame: Up to 24 hours postoperatively

  2. Serum Glucose level

    Blood serum level of glucose to assess metabolic stress.

    Time frame: Serum glucose: Baseline, just after incision, and 6 hours post-induction.

  3. Numerical Pain Distress Scale (NPDS) Score

    Self-reported pain intensity scored on an 11-point scale (0 = No pain to 10 = Unbearable pain). Higher number means high pain intensity.

    Time frame: Upon recovery in PACU and throughout the first 24 hours postoperatively.

  4. Ramsay Sedation Scale Score

    Assessment of sedation level scored from 1 (anxious or restless) to 6 (no response to stimulus).

    Time frame: Upon recovery in PACU and during the first 2 hours postoperatively.

  5. Intraoperative Analgesic Consumption

    Total intraoperative fentanyl consumption.

    Time frame: Intraoperatively measured from induction till end of surgery.

  6. Intraoperative Mean Arterial Pressure (MAP)

    Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

    Time frame: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

  7. Incidence of Side Effects and Complications

    Occurrence of postoperative nausea, vomiting, bradycardia, hypotension, or respiratory depression. It will be recorded as yes or No .

    Time frame: Up to 24 hours postoperatively.

  8. Lactate Level

    Blood serum lactate level to assess metabolic stress.

    Time frame: Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.

  9. Postoperative Analgesic Consumption

    Total postoperative meperidine consumption.

    Time frame: through 24 hours postoperatively.

  10. Intraoperative Anesthetic Consumption

    Total intraoperative consumption of isoflurane and average end-tidal concentration

    Time frame: Intraoperatively measured from induction till end of surgery.

  11. Intraoperative Heart Rate (HR)

    Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

    Time frame: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared in an open repository to protect participant privacy. Aggregate data and trial results will be published in a peer-reviewed journal upon study completion.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Nov 18, 2026
StartActual
Jan 10, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945171
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 10, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Tasneem Fathy Zahran, M.B.B.Ch., Master's Degree
Contact
TasneemFathy@med.asu.edu.eg
+20 1281946002
Hala said Hassan, MD
Contact
+201147784179

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion